Following its acquisition of Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), Amgen Inc. (NASDAQ:AMGN) will have at least six targeted cancer therapies in Phase II and Phase III, excluding line extensions and compounds to which worldwide rights have been out-licensed. The next readouts from Amgen's Phase III internal programs will come this year with survival data for Talimogene laherparepvec